Investigation of the possibility of using serum ischemia modified albumin (IMA) as a novel and early marker of the extent of oxidative stress induced by various tobacco products

Pavan R. Gothe, Maji Jose, Vinitha R. Pai, Sindhu Harish, Jyothi D’Souza, Vishnudas Prabhu

Research output: Contribution to journalArticle


Background: Ischemia Modified Albumin (IMA) is an altered serum albumin that forms under the conditions of oxidative stress and is considered as a biomarker of cardiac ischemia. The objective of this study was to evaluate the ischemia modified albumin (IMA) in the serum of the individuals with different types of tobacco habits in order to investigate the possibility of using this as a biomarker for the oxidative stress induced by the tobacco products. Materials and Methods: The study included 90 subjects, who were Grouped as control (30), Group I (betel quid chewers), Group II (gutkha chewers), Group III (smokers) and Group IV (mixed). Serum was collected from subjects of all Groups and IMA estimation was done using Albumin Cobalt binding assay. The results were tabulated and analysed statistically. Results: The mean serum IMA levels in control, Group I, Group II, Group III and Group IV were 0.52547 ABSU, 0.68767 ABSU, 0.47433 ABSU,0.36540 ABSU and 0.54593 ABSU respectively. Conclusion: The results show that serum IMA levels were increased in betel quid chewers and mixed Group compared to the controls. From the results noted in this study we suggest that IMA can be used as an early marker for tobacco related oxidative stress.

Original languageEnglish
Pages (from-to)ZC33-ZC35
JournalJournal of Clinical and Diagnostic Research
Issue number11
Publication statusPublished - 01-11-2015


All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry

Cite this